Compare KTCC & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTCC | MRKR |
|---|---|---|
| Founded | 1969 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 19.5M |
| IPO Year | 1995 | 2010 |
| Metric | KTCC | MRKR |
|---|---|---|
| Price | $1.35 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.87 |
| AVG Volume (30 Days) | 24.0K | ★ 182.9K |
| Earning Date | 11-03-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $467,871,000.00 | N/A |
| Revenue This Year | N/A | $19.61 |
| Revenue Next Year | N/A | $375.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.44 | $0.84 |
| 52 Week High | $4.42 | $2.46 |
| Indicator | KTCC | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 12.45 | 43.00 |
| Support Level | N/A | $0.88 |
| Resistance Level | $2.28 | $1.32 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 5.56 | 11.34 |
Key Tronic Corp is a contract manufacturer offering value-added design and manufacturing services from its facilities in the United States, Mexico, and Vietnam with procurement support from its facility in China. The company provides its customers full engineering services, materials management, manufacturing facilities, assembly services, in-house testing, and distribution. Its customers include original equipment manufacturers. Its capabilities are Printed Circuit Board Assembly, Injection Molding and Tooling, Metal Fabricating and Finishing, Full Product Assembly, Design and Engineering Support, and Logistics and Repair Center, and Supply Chain Management. It operates and internally manages a single operating segment, Electronics Manufacturing Services.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).